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As the evidence supporting metabolic deficiencies within skeletal muscle in cystic fibrosis (CF) 
grows, further consideration should be given to evaluating the potential clinical implications 
of these abnormalities. Specifically, it is important to determine how alterations at the cellular 
level may impact peripheral muscle function (e.g. strength, endurance and fatigability, e.g. 
Gruet et al. 2017). Studies exploring oxidative metabolism during upright cycling and cycling 
during 31P-magnetic resonance spectroscopy have provided crucial insight how central and 
peripheral factors may modulate oxidative metabolism in CF (Saynor et al. 2016; Werkman et 
al. 2016). However, such exercise testing does not permit us to fully infer the functional 
consequences of myocyte metabolic abnormalities to the locomotor muscles, since whole-body 
assessments of oxidative capacity may also reflect factors not specifically related to muscle 
(e.g. cardiac and/or pulmonary). Tasks that specifically localise a muscle group (e.g. 
quadriceps) with minimal cardiorespiratory constraint are thus also needed. Testing should 
ideally assess local muscle endurance and fatigability, by performing dynamic or isometric 
contractions at a relative intensity (percentage of maximal voluntary force), to control for 
differences in strength and/or muscle volume (often reduced in CF) (e.g. Gruet et al. 2016). 
However, as local exercise may not reflect day-to-day activities, we suggest a combined 
approach, assessing the relationship with whole-body exercise, is important. Using these 
complementary approaches will enable us to rule out or confirm the skeletal muscle metabolic 
abnormalities characterising CF and, importantly, their functional consequences. Multimodal 
assessments of aerobic fitness and skeletal muscle function, using reproducible tests (e.g. 
Bachasson et al. 2013; Saynor et al. 2013), represent an important next step in our 
understanding of how altered oxidative metabolism affects physical function in CF.    
 
 
Competing interest 
None declared 
 
References 
Bachasson D, Millet GY, Decorte N, Wuyam B, Levy P & Verges S (2013). Quadriceps function 
assessment using an incremental test and magnetic neurostimulation: a reliability study. J 
Electromyogr Kinesiol 23, 649-658. 
Gruet M, Decorte N, Mely L, Vallier JM, Camara B, Quetant S, Wuyam B & Verges S (2016). 
Skeletal muscle contractility and fatigability in adults with cystic fibrosis. J Cyst Fibros 15, 
e1-8. 
Gruet M, Troosters T & Verges S (2017). Peripheral muscle abnormalities in cystic fibrosis: Etiology, 
clinical implications and response to therapeutic interventions. J Cyst Fibros; DOI: S1569-
1993(17)30032-2 [pii] 101016/jjcf201702007. 
Saynor ZL, Barker AR, Oades PJ & Williams CA (2013). Reproducibility of maximal 
cardiopulmonary exercise testing for young cystic fibrosis patients. J Cyst Fibros 12, 644-
650. 
Saynor ZL, Barker AR, Oades PJ & Williams CA (2016). Impaired Pulmonary V O2 Kinetics in 
Cystic Fibrosis Depend on Exercise Intensity. Med Sci Sports Exerc 48, 2090-2099. 
Werkman M, Jeneson J, Helders P, Arets B, van der Ent K, Velthuis B, Nievelstein R, Takken T & 
Hulzebos E (2016). Exercise oxidative skeletal muscle metabolism in adolescents with cystic 
fibrosis. Exp Physiol 101, 421-431. 
 
 
 
 
 
